PDGFRA and lip and oral cavity carcinoma: We show here that treatment with crenolanib blocks activation of PDGFR-α (Figure 6A) and pretreated with 20 nM crenolanib significantly reduces the cisplatin dose response OSCCC cells grown in co-culture with MSCs compared to untreated MSC oral cancer cell co-cultures (Figure 6C; p < 0.0001).